



Crystal Watson, PhD (author)

Nancy Connell, PhD (presenter)
Senior Scholar and Professor
Johns Hopkins
Center for Health Security

TECHNOLOGIES TO ADDRESS
Global Catastrophic Biological Risks

Global Catastrophic Biological Risks (GCBRs)

- Global Catastrophic Risks are a class of risks – naturally or technologically driven – that have potential to inflict serious damage to human wellbeing on a global scale
- GCBRs might include:
 - Naturally occurring severe pandemics
 - Deliberately created and released pathogens
 - Laboratory engineered and escaped pathogens

Opportunities for Intervention Severe Pandemics

Prevent Spread
From Animals to
Humans or Detect
First Human Case

Identify First
Cluster and
Prevent an
Epidemic

Prevent
National and
International
Spread

Limits Spread
And Introduction
To Major Urban
Environments

Reduce
Morbidity
And
Mortality

Prevent
Existential
Risk to
Humanity



INDEX
CASE

INDEX
CLUSTER

LOCALIZED
EPIDEMIC

INTERNATIONAL
EPIDEMIC

GLOBAL
EPIDEMIC

Global Catastrophic
Biological Risk

Categories of Applicable Technologies


- Technologies can be applied at each of these inflection points in a number of ways to reduce biological risk, including through:
- Better detection, surveillance and characterization of a GCB event such that action can be taken to quickly prevent or quickly quell a biological event
- Increased response speed and global response reach in both resource-rich and low-resource-settings to mitigate the impacts of an unfolding event

Project Approach

- Structured exploration of **extant and emerging technologies** with the potential to radically alter the trajectory of severe infectious disease events with catastrophic potential
- **Goals:**
 - ID areas of need for tech solutions to address pandemic and GCBRs;
 - ID technologies that have significant potential to reduce GCBRs; and
 - Provide context for those technologies
- **Uses:** results should be used to guide further detailed analyses


Technology Evaluation Process

- Our Questions:
 - What is the technology?
 - What problem does it solve?
 - How do we do it now?
 - What does success look like?




Ubiquitous Genomic Sequencing and Sensing

- What is the technology?
 - Rapid, accurate, affordable, and fieldable nucleotide sequencing for detection of pathogens in human and environmental samples – nanopore sequencing
- What problem does it solve?
 - Sequencing can be used to detect novel or unexpected pathogens, whereas other molecular diagnostics like PCR only test for known pathogens
- How do we do it now?
 - Prior to nanopore, sequencing was centralized and laboratory-based
- What does success look like?
 - Ubiquitous sequencing will allow for the near real-time characterization of pathogen biology, including determinations of virulence, transmissibility, sensitivity or resistance to medicines or vaccines.




Cell-Free Diagnostics



- What is the technology?
 - Cell-free diagnostics take bioengineered cellular machinery from lysed cells, freeze dries these components, and uses them for diagnosis
- What problem does it solve?
 - It provides cheap, accurate, and portable diagnostics
- How do we do it now?
 - Diagnostics like polymerase chain reaction (PCR) require laboratories and expensive equipment
- What does success look like?
 - Cell-free diagnostics could be rapidly manufactured and distributed widely


3D Printing of Chemicals and Biologics

- What is the technology?
 - 3D printing (additive manufacturing) of drugs and vaccines
- What problem does it solve?
 - Even when a drug or vaccine is developed in time to respond to a pandemic, getting access to them will be difficult in many parts of the world. 3D printers could be used in doctors' offices, pharmacies, and even at home
- How do we do it now?
 - Most MCM manufacturing occurs at centralized sites and on dedicated platforms
- What does success look like?
 - 3D printing could allow for greater and earlier access to medical countermeasures developed in response to or identified in a GCB event



Synthetic Vaccinology: Self-Amplifying mRNA Vaccines

- What is the technology?
 - SAM vaccines use the genome of a modified RNA virus to introduce an antigen of interest and replicate in the body
- What problem does it solve?
 - Safer and easier to deliver than other nucleic acid vaccines
 - Reduces dose needed, and induces a broader immune response than other vaccines
- How do we do it now?
 - Viral vectors hampered by immune response and have risk of reversion to wild type
 - Large amounts of antigen and sometimes multiple doses and difficulty manufacturing
- What does success look like?
 - Fast, dose-sparing technology could mean a vaccine that is available rapidly and can protect many more people



Conclusions

- Technologies – while not a panacea – will be a critical part of the response to severe pandemics and GCBR's.
- Horizon scanning is a useful exercise to identify new technologies and use cases
- Scalable technology solutions will be needed if we're going to protect the health of 8 billion + individuals.
- Fortunately, with a few exceptions, most of the technologies that we think could make a difference either already exist, or are linear projections of the state of the art.

Call to Action

- Innovative thinking and a certain amount of risk taking will be required if humanity faces a major pandemic
- Routine and ongoing technology horizon scanning is needed to identify risks and benefits
- Dedicated thought and resources are needed to integrate technologies into practice in preparation for the next pandemic
- The next step is to do further analysis on use cases and viability of the highlighted technologies

Thank You!

Nancy Connell nancyconnell@jhu.edu

Crystal Watson cwatson@jhu.edu



JOHNS HOPKINS
BLOOMBERG SCHOOL
of PUBLIC HEALTH

**Center for
Health Security**